Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03947255
Title A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seattle Genetics, Inc.

peripheral T-cell lymphoma

Hodgkin's lymphoma

anaplastic large cell lymphoma


Brentuximab vedotin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.